International Journal of Cancer最新文献_第5页

Pre- and post-diagnostic meat intake in relation to risk of recurrence and mortality among individuals with stage I-III colorectal cancer. I-III期结直肠癌患者诊断前和诊断后肉类摄入量与复发和死亡风险的关系

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-18 DOI: 10.1002/ijc.70113

Anne-Sophie van Lanen, Dieuwertje E Kok, Evertine Wesselink, Jeroen W G Derksen, Anne M May, Karel C Smit, Miriam Koopman, Johannes H W de Wilt, Ellen Kampman, Fränzel J B van Duijnhoven

{"title":"Pre- and post-diagnostic meat intake in relation to risk of recurrence and mortality among individuals with stage I-III colorectal cancer.","authors":"Anne-Sophie van Lanen, Dieuwertje E Kok, Evertine Wesselink, Jeroen W G Derksen, Anne M May, Karel C Smit, Miriam Koopman, Johannes H W de Wilt, Ellen Kampman, Fränzel J B van Duijnhoven","doi":"10.1002/ijc.70113","DOIUrl":"https://doi.org/10.1002/ijc.70113","url":null,"abstract":"Processed meat and unprocessed red meat intakes are associated with increased colorectal cancer (CRC) risk, but evidence on associations with mortality after a CRC diagnosis is inconsistent. To date, no studies examined associations between unprocessed poultry intake and mortality, or assessed cancer recurrence risk as a separate outcome measure. We included data from 2484 individuals, who were newly diagnosed with stage I-III CRC, participating in 2 prospective cohort studies. Dietary intake was assessed at diagnosis and 6 months after diagnosis. Multivariable Cox proportional hazards regression models and restricted cubic splines were used to examine associations between pre- and post-diagnostic meat intake and risk of recurrence and all-cause mortality. We performed subgroup analyses by sex, disease stage and primary tumour location. During a median follow-up time of 5.0 years for recurrence analyses and 6.4 years for mortality analyses, 336 recurrences and 409 deaths occurred. Pre- and post-diagnostic processed meat and unprocessed red meat intakes were not associated with risk of recurrence nor all-cause mortality. At both timepoints, a higher unprocessed poultry intake was non-linearly associated with a decreased mortality risk, with the lowest risk observed at 20 g/day (hazard ratio: 0.63, 95% confidence interval: 0.47-0.85), compared to 0 g/day. Results were not substantially different by sex, disease stage and primary tumour location. To conclude, a higher pre- and post-diagnostic intake of unprocessed poultry, but not processed meat and unprocessed red meat, was associated with a decreased all-cause mortality risk in individuals with stage I-III CRC. Future studies in independent study populations should confirm these findings.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dosimetric and clinical predictors for radiation esophagitis in patients with breast cancer undergoing conventional fractionated regional nodal irradiation: A prospective study. 一项前瞻性研究：接受常规分次局部淋巴结照射的乳腺癌患者放射性食管炎的剂量学和临床预测因素。

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-18 DOI: 10.1002/ijc.70161

Dan-Qiong Wang, Dong-Xing Shen, Ning Han, Yu-Fei Lu, Wei-Fang Yang, Jian Tie, Xiao-Rong Hou, Xiao-Hong Wang, Ya-Hua Zhong, Xiao-Li Yu, Qiu-Zi Zhong, Jun Zhang, Na Zhang, Hao Jing, Hui Fang, Yu Tang, Yi-Rui Zhai, Ye-Xiong Li, Jun Ma, Li-Na Zhao, Shu-Lian Wang

{"title":"Dosimetric and clinical predictors for radiation esophagitis in patients with breast cancer undergoing conventional fractionated regional nodal irradiation: A prospective study.","authors":"Dan-Qiong Wang, Dong-Xing Shen, Ning Han, Yu-Fei Lu, Wei-Fang Yang, Jian Tie, Xiao-Rong Hou, Xiao-Hong Wang, Ya-Hua Zhong, Xiao-Li Yu, Qiu-Zi Zhong, Jun Zhang, Na Zhang, Hao Jing, Hui Fang, Yu Tang, Yi-Rui Zhai, Ye-Xiong Li, Jun Ma, Li-Na Zhao, Shu-Lian Wang","doi":"10.1002/ijc.70161","DOIUrl":"https://doi.org/10.1002/ijc.70161","url":null,"abstract":"This study aimed to determine dosimetric and clinical predictors of radiation esophagitis (RE) in breast cancer patients undergoing conventional fractionated regional nodal irradiation (RNI). Eligible patients received radiotherapy (RT; 50 Gy in 25 fractions) to the chest wall, supraclavicular/infraclavicular fossa, level II axilla, and/or internal mammary chain. RE was graded weekly during RT and at weeks 1, 2 and months 3, 6 post-RT (CTCAE v3.0). The esophagus was contoured from the lower edge of cricoid cartilage to aortic arch. Esophageal parameters included mean dose (Dmean), maximum dose (Dmax), relative (RV5-RV45) and absolute volumes (AV5-AV45) receiving 5-45 Gy in 5-Gy increments. Univariate and multivariate analyses identified predictors of grade ≥2 RE. Among 541 prospectively enrolled patients (minimum 6 months follow-up), 271 (50.1%) had left-sided breast cancer. Grade 2 RE was 23.7% (128/541), with no grade ≥3 RE. Tumor laterality (p < .001) was the only clinical risk factor. Esophageal Dmean, Dmax, RV20-RV40, and AV20-AV35 were dosimetric parameters of grade ≥2 RE in univariate analysis. Multivariate analysis identified RV30 <9% (13.9% vs. 31.3%) and AV30 <1 mL (15.2% vs. 30.5%) as optimal dosimetric predictors. Therefore, RE is common in patients receiving RNI, with tumor laterality being the clinical risk factor. Limiting upper esophagus RV30 <9% and AV30 <1 mL may reduce RE risk.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitor-induced vitiligo: A large-scale real world pharmacovigilance study. 免疫检查点抑制剂诱导的白癜风：一项大规模现实世界药物警戒研究。

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-18 DOI: 10.1002/ijc.70159

Bufu Tang, Yanming Yu, Juncheng Wan, Caihong Yu, Yiting Sun, Xinran Yu, Ruiqi Liu, Hairuo Huang, Yutong Du, Wenlu Hu, Miaohui Wang, Dandan Guo, Cheng Chi, Xudong Qu

{"title":"Immune checkpoint inhibitor-induced vitiligo: A large-scale real world pharmacovigilance study.","authors":"Bufu Tang, Yanming Yu, Juncheng Wan, Caihong Yu, Yiting Sun, Xinran Yu, Ruiqi Liu, Hairuo Huang, Yutong Du, Wenlu Hu, Miaohui Wang, Dandan Guo, Cheng Chi, Xudong Qu","doi":"10.1002/ijc.70159","DOIUrl":"https://doi.org/10.1002/ijc.70159","url":null,"abstract":"Although immune checkpoint inhibitors (ICI) have revolutionized cancer treatment paradigms, the associated immune-related adverse events (irAEs)-specifically vitiligo, which has demonstrated emerging prognostic significance-require further investigation. Using the FAERS database (2015Q1-2024Q3), we conducted a large-scale pharmacovigilance analysis to address the epidemiological and clinical knowledge gaps in ICI-associated vitiligo. Of the 162,022 reported ICI-related adverse events, 359 cases of vitiligo were identified (0.22%). Among these vitiligo cases, the three most common underlying malignancies were melanoma (59.4%), metastatic malignancies (28%, primarily metastatic melanoma and lung cancer), and lung cancer (6.8%). A disproportionality analysis utilizing reporting odds ratio (ROR), stratified by ICI class, cancer type, and patient characteristics, identified previously unreported associations between vitiligo and malignancies beyond melanoma. Generalized additive model (GAM) analysis demonstrated a significant non-linear relationship between WT and both the risk and temporal development pattern of vitiligo. This study confirms vitiligo as a multi-dimensional irAE with cross-tumor prognostic value and reveals the modulating role of metabolic factors on its clinical presentation, providing crucial scientific evidence for optimizing risk stratification and personalized immunotherapy strategies.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study. 不可切除的驱动阴性III期NSCLC治疗策略的实际有效性和安全性：一项回顾性多中心研究

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-18 DOI: 10.1002/ijc.70162

Mingjun Xu, Yan Xu, Yingchun Man, Xuqin Xiang, Dexin Jia, Junzhu Dai, Weitong Gao, Ruqiong Wang, Bo An, Kaile Zhao, Jiaojiao Li, Bo Pan, Yan Yu

{"title":"Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.","authors":"Mingjun Xu, Yan Xu, Yingchun Man, Xuqin Xiang, Dexin Jia, Junzhu Dai, Weitong Gao, Ruqiong Wang, Bo An, Kaile Zhao, Jiaojiao Li, Bo Pan, Yan Yu","doi":"10.1002/ijc.70162","DOIUrl":"https://doi.org/10.1002/ijc.70162","url":null,"abstract":"Concurrent or sequential chemoradiotherapy followed by immunotherapy (CCRT/SCRT→IO), known as the PACIFIC regimen, is the standard of care for unresectable, driver gene-negative Stage III non-small cell lung cancer (NSCLC). However, in real-world practice, some patients cannot proceed to immunotherapy due to toxicity, declining performance status, or disease progression. This multicenter retrospective study included 960 patients from 14 Chinese institutions (2011-2023) to evaluate the efficacy and safety of alternative regimens. Patients were stratified into five groups. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included objective response rate, disease control rate, duration of response, and immune-related adverse events (irAEs). Inverse probability treatment weighting was used to adjust for baseline differences. Among 911 evaluable patients, weighted median PFS was 21.7 months for (IO + CCRT/SCRT) → IO, 16.8 for (IO + Chemo) → IO, 25.8 for CCRT/SCRT → IO, 7.1 for chemotherapy alone, and 14.8 for CCRT/SCRT. Median OS was not reached in the (IO + CCRT/SCRT) → IO group and ranged from 31.1 to 58.3 months in others. No significant differences in PFS or OS were found between (IO + CCRT/SCRT) → IO and CCRT/SCRT → IO. Pneumonitis occurred most frequently in the CCRT/SCRT → IO group. Early initiation of IO did not significantly increase irAE risk. These findings support early integration of IO with chemoradiotherapy and maintenance IO as a viable option for unresectable Stage III NSCLC.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

WBP2 and its network of transcription coregulators in an expanding repertoire of human cancers. WBP2及其转录共调节因子网络在人类癌症中不断扩展。

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-16 DOI: 10.1002/ijc.70150

Amir Sabbaghian, Hexian Lin, Yoon Pin Lim

{"title":"WBP2 and its network of transcription coregulators in an expanding repertoire of human cancers.","authors":"Amir Sabbaghian, Hexian Lin, Yoon Pin Lim","doi":"10.1002/ijc.70150","DOIUrl":"https://doi.org/10.1002/ijc.70150","url":null,"abstract":"Dysregulation of transcription coregulators is common in cancers, supporting the key role for this group of proteins in cancer development. WW domain-binding protein 2 (WBP2) transcription coactivator is an emerging oncogene, first discovered in breast cancer and increasingly implicated in other human cancers except sex-related cancers. Here, we review the latest findings on the roles of WBP2 in human cancers and explore its function and network of transcriptional coregulators in ovarian and prostate cancers. Through the creation of a protein-interaction map of the sex hormone receptor coregulators, biologically meaningful observations and testable hypotheses were generated. Coupling the protein-interaction map with information from published literature reveals that the WBP2 transcription coactivator might play a role in ovarian and prostate cancers via protein complexes comprising Hippo pathway signaling components YAP and TAZ, Wnt pathway-related β-Catenin, and sex hormone receptor coregulators such as CBP/P300, NCOA3, and PGC-1α. Meta-analysis of public databases also revealed aberrant levels of these proteins in ovarian and prostate cancer, and found WBP2 overexpression in the immunoreactive ovarian cancer subtype, further supporting the role of these specific protein complexes in ovarian cancer. Finally, we reviewed the challenges in chemo and hormonal therapy and posit that WBP2-positive ovarian and prostate cancer might benefit from combinational therapy involving hormonal and immunotherapy.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mortality from cancer and non-cancer diseases in the Lithuanian cohort of Chernobyl cleanup workers (2001-2020). 立陶宛切尔诺贝利清理工人队列中癌症和非癌症疾病死亡率（2001-2020年）。

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-16 DOI: 10.1002/ijc.70155

Rita Steponaviciene, Ausrele Kesminiene, Auguste Kaceniene, Giedre Smailyte

{"title":"Mortality from cancer and non-cancer diseases in the Lithuanian cohort of Chernobyl cleanup workers (2001-2020).","authors":"Rita Steponaviciene, Ausrele Kesminiene, Auguste Kaceniene, Giedre Smailyte","doi":"10.1002/ijc.70155","DOIUrl":"https://doi.org/10.1002/ijc.70155","url":null,"abstract":"We examined the mortality risk from cancer and non-cancer diseases from 2001 to 2020 among Lithuanian Chernobyl cleanup workers exposed to ionizing radiation while working in areas contaminated by the Chernobyl nuclear power plant (NPP) accident. The mortality risk was estimated by calculating the standardized mortality ratio (SMR) with a 95% confidence interval (CI). A total of 1922 deaths were registered among the 5562 traced men. The all-cause mortality was slightly elevated (SMR = 1.07, 95% CI, 1.03-1.12), as was the mortality from all malignant neoplasms (SMR 1.15, 95% CI, 1.06-1.26), with the highest risk observed for smoking-related cancers (SMR 2.70, 95% CI, 2.44-2.99). The SMR for all circulatory diseases was also a little higher compared with the general Lithuanian male population (SMR 1.09, 95% CI, 1.02-1.18), particularly for cerebrovascular diseases (SMR 1.46, 95% CI, 1.22-1.74). For diseases of the circulatory system and all malignant neoplasms, the mortality risks were similar in both groups of documented external radiation doses (<100 and ≥100 mSv). The only exception pertains to hypertensive disease, where the SMR was higher in the dose group exceeding 100 mSv, compared with the dose group of ≤100 mSv (SMR 1.68, 95% CI, 1.03-2.74 vs. 1.4, 95% CI, 0.84-2.32, respectively). Continuing follow-up of mortality patterns of cancer and non-cancer diseases within the cohorts of Chernobyl cleanup workers provides important information about the long-term impact of the Chernobyl accident on health.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer. 多基因风险评分和前列腺特异性抗原预测中度侵袭性前列腺癌患者的死亡。

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-16 DOI: 10.1002/ijc.70163

Leandro Rodrigues Santiago, Efthymios Ladoukakis, Dorota Scibior-Bentkowska, Belinda Nedjai

{"title":"Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer.","authors":"Leandro Rodrigues Santiago, Efthymios Ladoukakis, Dorota Scibior-Bentkowska, Belinda Nedjai","doi":"10.1002/ijc.70163","DOIUrl":"https://doi.org/10.1002/ijc.70163","url":null,"abstract":"Polygenic risk scores (PRS) and the prostate specific antigen (PSA) test have been shown to be successful tools for predicting prostate cancer (PCa) incidence. In this study, we assessed the potential of combining PRS and PSA as biomarkers for PCa aggressiveness and subsequent mortality from patients with low to intermediate risk PCa from the TAPG-TURP cohort. Targeted sequencing of 140 PCa-related genes was performed using 162 prostate samples from PCa patients with a Gleason score of 6 or 7, 80 of whom died from the disease. An additional 305 genome samples from healthy participants of the 1000 Genomes Project phase 3 were selected as controls. Two novel PRSs were developed using 21 single nucleotide polymorphisms (SNPs) selected from those differentiated between alive (n = 82) and dead (n = 80) PCa patients. The first PRS was used in decision tree-based models, such as random forest (rf) able to accurately distinguish cancer from healthy samples (sensitivity = 100%, specificity = 100%, AUC = 1). The second PRS was used together with Gleason score and PSA in an artificial neural network model able to determine the aggressiveness of PCa by predicting PCa mortality with intermediate to high accuracy (sensitivity = 90%, specificity = 68.8%, AUC = 0.718). Further work must be done using our two machine learning classifiers to validate them further and apply them in the clinic, bypassing the necessity of invasive and more expensive approaches. Their application will potentially guide the clinical decision-making process and reduce costs of the clinical management of PCa patients.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145068673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex and organ-specific risk and temporal trends of human papillomavirus-associated anogenital cancer among solid organ transplant recipients in the United States. 美国实体器官移植受者中人类乳头瘤病毒相关的肛门生殖器癌的性别和器官特异性风险和时间趋势

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-15 DOI: 10.1002/ijc.70158

Jinhong Cui, Amrita Mukherjee, Pranali G Patel, Anna Junkins, Gaurav Agarwal, Smith Giri, Russell Griffin, Staci L Sudenga, Sadeep Shrestha

{"title":"Sex and organ-specific risk and temporal trends of human papillomavirus-associated anogenital cancer among solid organ transplant recipients in the United States.","authors":"Jinhong Cui, Amrita Mukherjee, Pranali G Patel, Anna Junkins, Gaurav Agarwal, Smith Giri, Russell Griffin, Staci L Sudenga, Sadeep Shrestha","doi":"10.1002/ijc.70158","DOIUrl":"https://doi.org/10.1002/ijc.70158","url":null,"abstract":"Solid organ transplant recipients (SOTRs) have an elevated risk of persistent infection of human papillomavirus (HPV) and associated anogenital (cervical, vulva, and vaginal among women, penile among men and anal among both men and women) cancers. Risk stratification and temporal trends of cancer incidence will help early detection, evaluation, management, and treatment of post-transplant cancers over time. We analyzed data of 239,613 heart, lung, liver, and kidney transplant recipients registered from 1987 to 2020 in the U.S. Scientific Registry of Transplant Recipients (SRTR) with cancer diagnosis reported during follow-up. There were 693 new cases of HPV-associated anogenital cancers, including 176 anal, 118 cervical, 310 vulvar, and 89 penile cancers. The age-adjusted incidence rates and confidence intervals (IRs [95% CI] per 100,000 person-years) were anal (10.5 [9.1, 12.2]), cervical (17 [14.2, 20.4]), vulvar (44.2 [39.5, 49.4]), and penile (9.0 [7.3, 11.1]). Overall, the risk of all cancers among SOTRs remains elevated compared with the U.S. general population: standardized incidence ratio (SIR) for anal (2.73 [2.34, 3.14]), cervical (1.46 [1.21, 1.73]), vulvar (8.82 [7.87, 9.83]), and penile (6.13 [3.38, 9.70]). Lung recipients showed the highest IR for anal, vulvar, and penile cancer, while heart recipients demonstrated the highest IR for cervical cancer. Similarly, the 10-year cumulative incidence (per 100,000 persons) of anal (124), vulvar (523) and penile (95) cancer was highest among lung recipients, while the highest cumulative incidence of cervical cancer (231) was among heart recipients. These data can help develop risk stratification for HPV-associated cancer screening and management among SOTRs.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era. 流行病学方法评估HPV疫苗接种时代HPV相关宫颈病变的临床揭露。

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-15 DOI: 10.1002/ijc.70119

Joseph E Tota, Jaimie Z Shing, Jeffrey N Roberts, Elizabeth M Anderson, Alfred J Saah, Ariana Harari, Eduardo L Franco, Melvin Kohn, Susanne K Kjær

{"title":"Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era.","authors":"Joseph E Tota, Jaimie Z Shing, Jeffrey N Roberts, Elizabeth M Anderson, Alfred J Saah, Ariana Harari, Eduardo L Franco, Melvin Kohn, Susanne K Kjær","doi":"10.1002/ijc.70119","DOIUrl":"https://doi.org/10.1002/ijc.70119","url":null,"abstract":"HPV vaccination reduces the risk of developing HPV-attributable cancers, including cervical cancer. However, an attenuation of HPV vaccine impact after the implementation of HPV vaccination may occur through clinical unmasking. Clinical unmasking is a distinct and complex phenomenon that arises in the absence of clinical interventions necessary to treat disease caused by high-risk vaccine-preventable HPV types (mainly HPV16) allowing uninterrupted progression of non-vaccine preventable types that are frequently present as co-infections. Clinical unmasking is distinct from viral unmasking, which is a diagnostic assay artifact, and from HPV type replacement, a theorized biological phenomenon requiring competition between HPV types, which has not yet been documented. All three processes could manifest as an apparent increase in cervical precancer/cancer by non-HPV vaccine types, resulting in a lower-than-anticipated vaccine impact based on projections derived from type attribution studies. Here, we describe these concepts and epidemiological approaches to evaluate clinical unmasking in the post-vaccination era. We propose a historical and a contemporaneous approach, highlighting key considerations and illustrating the potential outcomes with hypothetical data. Both approaches would have a similar outcome and interpretation: an increased incidence of precancerous lesions (CIN2+) due to non-vaccine preventable types among vaccinated versus unvaccinated women (historically in the pre-vaccination era, or contemporaneously) in the long term being indicative of clinical unmasking. Protection afforded by HPV vaccines against high-grade cervical precancers, irrespective of type, remains considerable. However, carefully designed studies are needed to investigate the potential impact of clinical unmasking and its implications on vaccine effectiveness in the post-vaccination era.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemotherapy as a double-edged sword: Modulation of tumor-associated cytokine and chemokine responses in ovarian cancer. 化疗是一把双刃剑：卵巢癌中肿瘤相关细胞因子和趋化因子反应的调节。

IF 4.7 2区医学

International Journal of Cancer Pub Date : 2025-09-15 DOI: 10.1002/ijc.70132

Amin Ullah, Yongxiu Chen, Yuan Shen, Bairong Shen

{"title":"Chemotherapy as a double-edged sword: Modulation of tumor-associated cytokine and chemokine responses in ovarian cancer.","authors":"Amin Ullah, Yongxiu Chen, Yuan Shen, Bairong Shen","doi":"10.1002/ijc.70132","DOIUrl":"https://doi.org/10.1002/ijc.70132","url":null,"abstract":"Ovarian cancer (OC) is one of the most lethal gynecological malignancies, with high recurrence rates and chemoresistance posing significant challenges to effective treatment. Platinum-based agents, such as cisplatin and carboplatin, along with taxanes, including paclitaxel and docetaxel, represent fundamental therapies for OC. However, the immunomodulatory effects of these agents on the tumor microenvironment are multifaceted and can be perceived as a double-edged sword. Chemotherapeutics not only trigger cytotoxic effects but also influence the networks of pro- and anti-tumor cytokines, playing a role in both treatment efficacy and resistance. We specifically examine cytokine-mediated mechanisms underlying both platinum-based and taxane-based chemoresistance in OC. In this review, we comprehensively examine how platinum and taxane chemotherapy modulate cytokine signaling in OC, focusing on key mediators like interleukin (IL) 6, IL-8, transforming growth factor-beta, and C-X-C motif ligand 2 that drive survival pathways and chemoresistance. Interestingly, these agents might enhance anti-tumor immunity via interferon-gamma and IL-12, revealing the potential for synergistic chemoimmunotherapy. This research provides valuable insights for addressing resistance and improving combination therapies through the analysis of the dual roles of chemotherapy in modulating cytokine dynamics in OC.","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0